Clinical Annotation ID	Evidence ID	Evidence Type	Evidence URL	PMID	Summary	Score
1450375701	1450375663	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450375663	30924126.0	Allele C is associated with increased response to allopurinol.	0.0
1043880328	827778899	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827778899	21435719.0	Genotype AA is associated with increased likelihood of Neurotoxicity when treated with thalidomide in people with Multiple Myeloma as compared to genotype AG.	1.5
1183680546	PA166110235	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166110235		Annotation of CPIC Guideline for peginterferon alfa-2a,peginterferon alfa-2b,ribavirin and IFNL3	100
1183680546	PA166104801	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104801		Annotation of FDA Label for peginterferon alfa-2b and IFNL3	100
1183680546	1448568054	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448568054	27711230.0	Genotype CC is associated with increased sustained virological response (svr) when treated with boceprevir, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.5
1183680546	981240127	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981240127	22626609.0	Genotype CC is associated with increased sustained virological response (svr) when treated with boceprevir, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	3.0
1183680546	1447676829	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447676829	26191484.0	Genotype CC is associated with increased response to boceprevir, peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C as compared to genotypes CT + TT.	2.0
1183680546	1447682452	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682452	26670100.0	Allele C is associated with increased response to boceprevir, peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to allele T.	3.25
1183680546	1448617734	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448617734	28469811.0	Genotype CC is associated with increased sustained virological response (svr) when treated with boceprevir, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.5
981419260	PA166105003	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166105003		Annotation of CPIC Guideline for allopurinol and HLA-B	100
981419260	827919454	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827919454	21545408.0	HLA-B *58:01 is associated with increased likelihood of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with allopurinol in people with Drug Hypersensitivity.	0.0
981419260	981345627	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981345627	21393610.0	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in people with Kidney Failure, Chronic.	3.75
981419260	981345632	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981345632	21301380.0	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	4.0
981419260	981345637	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981345637	19696695.0	HLA-B *58:01 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.	2.75
981419260	981345642	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981345642	19018717.0	HLA-B *58:01 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with allopurinol.	3.5
981419260	981345647	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981345647	18192896.0	HLA-B *58:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with allopurinol in people with Drug Hypersensitivity.	3.0
981419260	981345654	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981345654	15743917.0	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	3.0
981419260	981419988	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419988	22909208.0	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in people with Arthritis, Gouty.	3.5
981419260	981420004	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981420004	22909208.0	HLA-B *58:01/*58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in people with Arthritis, Gouty.	2.75
981419260	1183682459	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183682459	23669020.0	HLA-B *58:01 is associated with increased risk of erythema exudativum multiforme or Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.	2.5
981419260	1183682532	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183682532	23600531.0	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in people with Hyperuricemia.	2.5
981419260	1183682546	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183682546	23280169.0	HLA-B *58:01 is associated with Stevens-Johnson Syndrome when treated with allopurinol in men with Gout.	0.25
981419260	1183682555	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183682555	22348415.0	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	3.0
981419260	1183682626	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183682626	21906289.0	HLA-B *58:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with allopurinol.	2.0
981419260	1183685075	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685075	17587850.0	HLA-B *58:01 is associated with Drug Hypersensitivity when treated with allopurinol in men.	0.25
981419260	1183685103	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685103	22017528.0	HLA-B *58:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.	3.5
981419260	1183685113	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685113	19483528.0	HLA-B *58:01 is associated with Epidermal Necrolysis, Toxic when treated with allopurinol in children with Hyperuricemia.	0.25
981419260	1183685121	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685121	22901319.0	HLA-B *58:01 is associated with drug reaction with eosinophilia and systemic symptoms when treated with allopurinol in men with Hyperuricemia.	0.25
981419260	1183685128	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685128	21790926.0	HLA-B *58:01 is associated with Drug Hypersensitivity when treated with allopurinol.	0.25
981419260	1184467886	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467886	21912425.0	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	3.5
981419260	1184470833	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184470833	24858023.0	HLA-B *58:01 is not associated with risk of Drug Hypersensitivity when treated with allopurinol in people with Hematologic Neoplasms.	-1.75
981419260	1184748340	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184748340	25115449.0	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	3.0
981419260	1184755884	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184755884	19002350.0	HLA-B *58:01 is not associated with increased risk of Drug Hypersensitivity and drug reaction with eosinophilia and systemic symptoms when treated with allopurinol in people with severe cutaneous adverse reactions.	-0.25
981419260	1184756798	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184756798	21393610.0	HLA-B *58:01 is not associated with increased risk of Exanthema when treated with allopurinol in people with Kidney Failure, Chronic.	-0.625
981419260	1184987721	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184987721	25257159.0	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	2.75
981419260	1184998111	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184998111	25327504.0	HLA-B *58:01 is associated with Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol in people with Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome.	1.5
981419260	1445362018	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445362018	26104483.0	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	3.5
981419260	1447672343	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672343	26632391.0	HLA-B *58:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol.	3.5
981419260	1447676605	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447676605	26655481.0	HLA-B *58:01 is associated with risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol.	1.0
981419260	1447949095	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447949095	26937673.0	HLA-B *58:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with allopurinol.	0.25
981419260	1448255668	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448255668	26996548.0	HLA-B *58:01 is associated with increased risk of Maculopapular Exanthema and severe cutaneous adverse reactions when treated with allopurinol.	3.75
981419260	1448256105	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448256105	27486401.0	HLA-B *58:01 is associated with increased risk of Maculopapular Exanthema and severe cutaneous adverse reactions when treated with allopurinol.	3.5
981419260	1448530471	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448530471	25899558.0	HLA-B *58:01 is associated with Stevens-Johnson Syndrome when treated with allopurinol.	0.25
981419260	1448624570	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448624570	28509689.0	HLA-B *58:01:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with allopurinol.	3.0
981419260	1448997619	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448997619	28857441.0	HLA-B *58:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol.	4.0
981419260	1449170079	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449170079	29392141.0	HLA-B *58:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms and Stevens-Johnson Syndrome when treated with allopurinol.	3.75
981419260	1450342159	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450342159	30383575.0	HLA-B *58:01 is associated with increased risk of Epidermal Necrolysis, Toxic when treated with allopurinol.	0.25
981419260	1451211440	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451211440	32433341.0	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	3.25
981419260	1446902249	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446902249	25566896.0	HLA-B *58:01 is associated with Drug Hypersensitivity and Exanthema when treated with allopurinol.	0.25
981419260	1448429006	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448429006	27835909.0	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	2.0
1449309937	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1449309937	1449275168	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449275168	27857962.0	Allele del is associated with increased risk of Malignant Hyperthermia when treated with isoflurane or sevoflurane in children as compared to allele GAG.	0.25
1449309937	1449310291	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449310291	11389482.0	Allele GAG is associated with increased risk of Malignant Hyperthermia when exposed to halothane, isoflurane or succinylcholine as compared to allele del.	0.25
1447680028	1447678770	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447678770	26633805.0	Genotypes ATTTGTTCATGCCT/ATTTGTTCATGCCT + ATTTGTTCATGCCT/del is associated with increased response to capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype del/del.	3.25
1448603303	1448603169	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448603169	25558980.0	Genotypes AA + AG is associated with increased risk of Postoperative Nausea and Vomiting when treated with morphine in children as compared to genotype GG.	3.0
1444668808	1183615560	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183615560	11593098.0	Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with increased response to irbesartan in people with Hypertension as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del.	2.0
1444668808	1451493552	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451493552	11910301.0	Allele ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is not associated with response to atenolol or irbesartan in people with Hypertrophy, Left Ventricular as compared to allele del.	-1.25
1451114960	827811344	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827811344	19384296.0	Allele (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 is not associated with survival when treated with fluorouracil in people with Colorectal Neoplasms.	-1.5
1451114960	827813351	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827813351	21919605.0	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is associated with decreased response to fluorouracil in people with Colorectal Neoplasms.	-3.5
1451114960	769261466	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769261466	20385995.0	Genotypes (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/3 are associated with increased progression-free survival when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotype 33.	2.75
1451114960	1184468622	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184468622	20165956.0	Genotypes (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/3 is associated with increased response to fluorouracil in people with Rectal Neoplasms as compared to genotype 33.	1.75
1451114960	1184469575	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184469575	20932673.0	Genotype (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 is not associated with response to fluorouracil in people with Rectal Neoplasms.	-1.0
1451114960	769169069	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169069	14522928.0	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is associated with increased overall survival when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.	2.0
1451114960	769169217	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769169217	15918040.0	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is associated with decreased response to fluorouracil in people with as compared to genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2.	0.0
1451114960	769165179	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769165179	21167658.0	Genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is associated with increased response to fluorouracil in people with Rectal Neoplasms as compared to genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2.	-1.75
1451114960	827813447	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827813447	20665215.0	Allele (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is not associated with response to fluorouracil in people with Colonic Neoplasms as compared to allele (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.	-1.25
1451114960	1184886844	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184886844	25232828.0	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is associated with increased response to fluorouracil, leucovorin and oxaliplatin in people with Esophageal Neoplasms and Stomach Neoplasms as compared to genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.	1.5
1451114960	827825053	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827825053	16249645.0	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is associated with increased survival when treated with cisplatin and fluorouracil in people with Stomach Neoplasms.	0.25
1451114960	769169082	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769169082	11913730.0	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is associated with increased response to fluorouracil in people with Colorectal Neoplasms as compared to genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.	1.5
1451114960	1449155868	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449155868	28972045.0	Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is associated with increased overall survival when treated with cisplatin, epirubicin and fluorouracil in people with Esophageal Neoplasms or Stomach Neoplasms as compared to genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.	2.5
